Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.69−0.02 (-3.12%)
Close on Nov 13, 2026Market cap $26.13MP/E –Yield –
Metagenomi Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Metagenomi Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $80.85M, down 15.9% year over year. For fiscal 2025 it was $94.43M, down 13.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.43M | -13.5% |
| FY2024 | Dec 31, 2024 | $109.18M | +15.7% |
| FY2023 | Dec 31, 2023 | $94.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.53M | -30.7% |
| Q2 FY2026 | Jun 30, 2026 | $22.51M | +0.0% |
| Q1 FY2026 | Mar 31, 2026 | $19.30M | -23.2% |
| Q4 FY2025 | Dec 31, 2025 | $21.50M | -7.2% |
| Q3 FY2025 | Sep 30, 2025 | $25.28M | -3.7% |
| Q2 FY2025 | Jun 30, 2025 | $22.51M | -20.5% |
| Q1 FY2025 | Mar 31, 2025 | $25.14M | -20.0% |
| Q4 FY2024 | Dec 31, 2024 | $23.16M | -6.4% |
| Q3 FY2024 | Sep 30, 2024 | $26.26M | -2.2% |
| Q2 FY2024 | Jun 30, 2024 | $28.32M | +24.9% |
| Q1 FY2024 | Mar 31, 2024 | $31.44M | +56.2% |
| Q4 FY2023 | Dec 31, 2023 | $24.76M | – |
| Q3 FY2023 | Sep 30, 2023 | $26.84M | – |
| Q2 FY2023 | Jun 30, 2023 | $22.68M | – |
| Q1 FY2023 | Mar 31, 2023 | $20.13M | – |
See a number that looks wrong?